Publications by authors named "Yang-Yang Qi"

Article Synopsis
  • - The study evaluated the safety and effectiveness of a new bivalent HPV vaccine (HPV-2) in 9-14 year-old girls and compared it with a three-dose schedule in 18-26 year-old women to see if fewer doses could still provide similar immunity.
  • - Conducted in Guangxi, China, 600 girls received either two or three vaccine doses while 300 women received three doses, showing significant increases in neutralizing antibodies that lasted at least 36 months.
  • - Results indicated that the immune response in girls who received two doses was comparable to that of women who received three doses, with vaccination being well tolerated and no serious side effects reported.
View Article and Find Full Text PDF

Acute gastroenteritis (AGE) caused by rotavirus (RV) remains a public health issue in China. To accelerate the mass rotavirus vaccination, it is important to inform the policy maker, and the public of the economic burden caused by rotavirus infection. A meta-analysis was conducted applying standardized algorithms.

View Article and Find Full Text PDF

The effectiveness of the vero cell inactivated vaccine (CoronaVac®) against severe acute respiratory infection (‎SARI)‎ caused by SARS-CoV-2 in the real world was assessed. A matched test-negative case-control design was employed using the web-based national information system, as well as the hospitalization dataset in Sibu Hospital. Vaccine effectiveness was measured by conditional logistic regression with adjustment for gender, underlying comorbidity, smoking status, and education level.

View Article and Find Full Text PDF

Waning of neutralizing titres along with decline of protection efficacy after the second dose of COVID-19 vaccines was observed, including China-made inactivated vaccines. Efficacy of a heterologous boosting using one dose of a recombinant SARS-CoV-2 fusion protein vaccine (V-01) in inactivated vaccine-primed population was studied, aimed to restore the immunity. A randomized, double-blind and placebo-controlled phase III trial was conducted in healthy people aged 18 years or older in Pakistan and Malaysia.

View Article and Find Full Text PDF